# Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

> **NCT00741325** · — · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 178 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Autologous Transplantation

## Interventions

- **DRUG:** granulocyte colony-stimulating factor (G-CSF)
- **DRUG:** plerixafor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00741325
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741325, "Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00741325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*